The baseline ALT levels of SMA patients were basically within the normal range, except for two patients with mild elevation, and there was no significant change in ALT compared to the baseline levels after three rounds of treatment with nusinersen (P1 = 0.109, P2 = 0.796, P3 = 0.537; Figure 3A). The gene discussed is GPT; the disease is proximal spinal muscular atrophy.